01725nas a2200373   4500000000100000008004100001260001300042653002700055653002400082653003900106653002700145653001600172653001100188653002900199653002400228653001200252653002600264653002800290653002000318653002100338653002900359653002600388653002200414653001800436653002800454100001500482700001100497700001300508245008400521300000900605490000700614520071600621022001401337       1993                            d  c1993 Jan10aAdjuvants, Immunologic10aAmino Acid Sequence10aEnkephalin, D-Penicillamine (2,5)-10aEnkephalin, Methionine10aEnkephalins10aHumans10aImmunosuppressive Agents10aIn Vitro Techniques10aleprosy10aLymphocyte Activation10aMolecular Sequence Data10aOpioid Peptides10aPeptides, Cyclic10aReceptors, Opioid, delta10aReceptors, Opioid, mu10aRosette Formation10aT-Lymphocytes10aTuberculosis, Pulmonary1 aMazumder S1 aNath I1 aDhar M M00aImmunomodulation of human T cell responses with receptor selective enkephalins.  a33-80 v353 a<p>The delta-opioid receptor selective [2-D-penicillamine-5-D-penicillamine] enkephalin (DPDPE) and the mu receptor selective Tyr-D-Orn-Phe-Asp-NH2 (TOPA) were found respectively, to have marked immunostimulant and immunosuppressant activities in both normal subjects and patients suffering from leprosy and tuberculosis. Antigen specific lymphoproliferation and numbers of rosette forming T cells were significantly (P < 0.05) enhanced on in vitro treatment with Met-enkephalin. This was further increased (P < 0.001) in the presence of the delta selective DPDPE. In contrast, treatment with mu selective TOPA inhibited lymphoproliferation substantially (P < 0.01) and rosette formation to a lesser extent.</p>  a0165-2478